Impact of proton pump inhibitors and histamine-2-receptor antagonists on non-small cell lung cancer immunotherapy: a systematic review and meta-analysis
A Rizzo, A Cusmai, F Giovannelli, S Acquafredda… - Cancers, 2022 - mdpi.com
Simple Summary The current meta-analysis highlighted that proton pump inhibitors (PPIs)
and histamine-2-receptor antagonists (H2RAs) could impact immune checkpoint inhibitors …
and histamine-2-receptor antagonists (H2RAs) could impact immune checkpoint inhibitors …
Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis
S Lopes, L Pabst, A Dory, M Klotz, B Gourieux… - Frontiers in …, 2023 - frontiersin.org
Introduction Gut microbiota can significantly affect the effectiveness of immune checkpoint
inhibitors (ICIs) in cancer patients. Recently, antibiotics were shown to decrease survival …
inhibitors (ICIs) in cancer patients. Recently, antibiotics were shown to decrease survival …
An up-to-date investigation into the correlation between proton pump inhibitor use and the clinical efficacy of immune checkpoint inhibitors in advanced solid cancers …
C Liu, H Guo, H Mao, J Tong, M Yang, X Yan - Frontiers in Oncology, 2022 - frontiersin.org
Background Although immune checkpoint inhibitors (ICIs) have revolutionized the current
anticancer therapies, a considerable proportion of patients are found to hardly benefit from …
anticancer therapies, a considerable proportion of patients are found to hardly benefit from …
A systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of cancer patients treated with immune checkpoint inhibitors
A Crespin, C Le Bescop, J de Gunzburg, F Vitry… - Frontiers in …, 2023 - frontiersin.org
Background Immune checkpoint inhibitors (ICIs) have considerably improved patient
outcomes in various cancer types, but their efficacy remains poorly predictable among …
outcomes in various cancer types, but their efficacy remains poorly predictable among …
[HTML][HTML] Drug–drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure
New concepts and drugs have revolutionized medical treatment for cancers. These drugs,
which are very expensive and usually well tolerated, have dramatically improved cancer …
which are very expensive and usually well tolerated, have dramatically improved cancer …
Comedications with immune checkpoint inhibitors: involvement of the microbiota, impact on efficacy and practical implications
J Colard-Thomas, QD Thomas, M Viala - Cancers, 2023 - mdpi.com
Simple Summary Since the approval of immune checkpoint inhibitors for solid tumors,
concerns have been raised about the role of the microbiota on immunotherapy success and …
concerns have been raised about the role of the microbiota on immunotherapy success and …
The association between baseline proton pump inhibitors, immune checkpoint inhibitors, and chemotherapy: a systematic review with network meta-analysis
Y Chang, WY Lin, YC Chang, CH Huang, HE Tzeng… - Cancers, 2022 - mdpi.com
Simple Summary Proton pump inhibitors (PPIs) are the most commonly used gastric acid
suppressants in cancer patients. However, long-term use of PPIs can cause dysbiosis effects …
suppressants in cancer patients. However, long-term use of PPIs can cause dysbiosis effects …
Concomitant use of statins, metformin, or proton pump inhibitors in patients with advanced renal cell carcinoma treated with first-line combination therapies
M Santoni, J Molina-Cerrillo, ZW Myint, F Massari… - Targeted Oncology, 2022 - Springer
Background Drug–drug interactions are a major concern in oncology and may potentially
affect the outcome of patients with cancer. Objective In this study, we aimed to determine …
affect the outcome of patients with cancer. Objective In this study, we aimed to determine …
[HTML][HTML] Impact of proton-pump inhibitors on the efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis
S Dar, N Merza, M Rahim, A Qatani… - Annals of Medicine and …, 2022 - Elsevier
Introduction Immune checkpoint inhibitors (ICI) is a rapidly evolving treatment modality for
stage IV non-small cell lung cancer (NSCLC). Concomitant proton pump inhibitor (PPI) use …
stage IV non-small cell lung cancer (NSCLC). Concomitant proton pump inhibitor (PPI) use …
Acid suppressants reduce the therapeutic effect of immune checkpoint inhibitors and increase the risk of acute kidney injury: a meta-analysis
K Okamoto, Y Saito, A Yamaguchi, Y Takekuma… - International Journal of …, 2023 - Springer
Abstract Background Immune checkpoint inhibitors (ICIs) are used in cancer
immunotherapy; however, they can lead to immune-related adverse events (irAEs) through …
immunotherapy; however, they can lead to immune-related adverse events (irAEs) through …